Basal Cell Carcinoma Review

Dennis P Kim; Kylee J B Kus; Emily Ruiz

doi:10.1016/j.hoc.2018.09.004

Basal Cell Carcinoma Review

Hematol Oncol Clin North Am. 2019 Feb;33(1):13-24. doi: 10.1016/j.hoc.2018.09.004.

Authors

Dennis P Kim¹, Kylee J B Kus², Emily Ruiz³

Affiliations

¹ Mohs Micrographic Surgery, Brigham and Women's Faulkner Hospital, 1153 Centre Street, Suite 4J, Jamaica Plain, MA 02130-3446, USA.
² Oakland University William Beaumont School of Medicine, 586 Pioneer Drive, Rochester, MI 48309-4482, USA.
³ High-Risk Skin Cancer Clinic, Dana Farber/Brigham and Women's Cancer Center, Mohs and Dermatologic Surgery Center, Brigham and Women's Faulkner Hospital, Harvard Medical School, 1153 Centre Street, Suite 4J, Jamaica Plain, MA 02130-3446, USA. Electronic address: esruiz@bwh.harvard.edu.

PMID: 30497670
DOI: 10.1016/j.hoc.2018.09.004

Abstract

Basal cell carcinoma (BCC) is the most common malignancy and the incidence is rising. BCCs have low mortality but can cause significant morbidity primarily through local destruction. The pathogenesis is linked to the interplay between environmental and patient-derived characteristics. There are multiple therapeutic modalities, and appropriate selection requires knowledge of complications, cosmetic outcomes, and recurrence rates. This article reviews the epidemiology, staging, treatment, and prevention of BCC.

Keywords: BCC; Basal cell carcinoma; MMS; Mohs; NMSC; Nonmelanoma skin cancer.

Publication types

Review

MeSH terms

Carcinoma, Basal Cell / diagnosis*
Carcinoma, Basal Cell / epidemiology
Carcinoma, Basal Cell / etiology
Carcinoma, Basal Cell / therapy*
Combined Modality Therapy
Disease Management
Disease Susceptibility
Humans
Incidence
Neoplasm Grading
Neoplasm Staging
Risk Factors
Skin Neoplasms / diagnosis
Skin Neoplasms / epidemiology
Skin Neoplasms / etiology
Skin Neoplasms / therapy
Treatment Outcome